Dr. Weiss on Developments in the Treatment of Head and Neck Cancer

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses developments of immunotherapy trials for patients with head and neck cancer.

There is a trial of pembrolizumab (Keytruda) in combination with radiation, which might one day replace cisplatin, explains Weiss.

There is also a study investigating durvalumab (Imfinzi) with carboplatin and nab-paclitaxel (Abraxane) as induction chemotherapy prior to surgery for hard-to-cure patients, states Weiss.